A critical assessment of the $70M round for smart-ring maker Ultrahuman, led by Qualcomm Ventures at a $365M valuation. It is the only major ring maker Oura has kept banned from the US rather than licensed — and the company a federal adjudicator found had falsified evidence about a US factory, the same US-manufacturing story now central to its survival.
The US ITC banned Ultrahuman's original ring effective Oct 21, 2025, finding Oura's patent claims valid and infringed on “every element.” RingConn and Circular settled and licensed; Ultrahuman is the only major maker still boxed out. Its Ring Pro workaround clears US customs only conditionally — and Oura has filed a fresh Texas suit against it and its US manufacturer.
Management tells the press $140M ARR. The India entity's audited FY25 filing shows ~$68M revenue and a real profit — yet the company also says it “may not be profitable in 2026.” The $140M is a forward-annualized, self-reported run-rate roughly 2x the last audited top line. Treat it as marketing, not accounting.
On-device AI, a game-controller mode, and a developer platform collide with a coin-cell energy budget, thermal limits, and antenna physics inside a titanium band. The thesis is a chip vendor's platform fantasy — Qualcomm wants a new silicon socket — not a demonstrated product. It is promised for “end of September.”
Key Finding: Ultrahuman has a real, profitable hardware business and a genuine differentiator — no mandatory subscription vs. Oura's ~$5.99/mo. But the single most under-reported fact is that the ITC found the company “falsified evidence regarding a Texas manufacturing facility” — the same US-manufacturing capability now load-bearing for its post-ban survival and its largest revenue market (~45% US). That finding, plus the unreconciled $140M-ARR-vs-$68M-audited gap, are governance red flags no S-1 or acquirer will miss.
The round coverage frames Ultrahuman as an AI-hardware story. The load-bearing fact is a US import ban and a falsified-evidence finding that the funding news never mentions.
Aug 2025: ITC finds Oura's claims valid and infringed on “every element of every asserted claim.”
Oct 21, 2025: exclusion + cease-and-desist orders take effect. Original ring barred from US import and sale.
RingConn and Circular settle and license with Oura; Luna Ring exits the US. Ultrahuman does not settle.
Mar 6, 2026: US CBP agrees the redesigned Ring Pro is not covered — but reserves the right to demand CT scans and records.
Oura files a fresh Texas suit targeting the Ring Pro and Ultrahuman's US manufacturing partner.
The ITC's initial determination held that Ultrahuman falsified evidence regarding a Texas manufacturing facility. This is not a footnote. US manufacturing is now the linchpin of Ultrahuman's plan to keep selling in the US — its largest market at ~45% of revenue — and its Ring Pro clears customs only conditionally. A federal adjudicator found the company fabricated proof about the very capability its survival now depends on. For a firm citing “eight quarters of profitability” ahead of a 2028 IPO, an on-record finding of falsified evidence is a diligence landmine.
The differentiator that is real: Ultrahuman charges no mandatory subscription — Ring Pro is a one-time purchase, while Oura requires ~$5.99/mo for full data access. That is a genuine pricing advantage. It is a choice, not a moat, and it does not survive a second adverse ruling.
Ultrahuman is challenging a leader with 80% share and ~30x its capital — in a category whose entire 2025 revenue (~$417M) was smaller than the valuations being thrown around.
Market leader with >80% global share (IDC). ~$900M raised, confidential IPO filed May 2026. The litigant that banned Ultrahuman and is now suing again in Texas. ~30x Ultrahuman's valuation.
Raised $575M in March 2026. Wrist band, subscription model. Not a ring, but the same recovery/longevity buyer — and vastly better capitalized than Ultrahuman.
$399, no subscription, backed by Samsung's distribution and ecosystem. No successor since Jul 2024; a Ring 2 isn't expected until early 2027 — the one window Ultrahuman can exploit.
The tell: RingConn, Circular, and Luna Ring all took Oura's licensing offer or exited. Ultrahuman is the only rival Oura has refused to license — a signal that the leader sees it as the threat worth boxing out entirely, and that the legal fight is a feature of Ultrahuman's life, not a one-time event.
Seven structural risks — four of them High — that the round narrative sidesteps.
Only major ring maker still under a US ban on its original product. A second Texas suit targets the Ring Pro workaround and the US manufacturing partner. A loss removes ~45% of revenue mid-IPO-runway.
A federal adjudicator found Ultrahuman fabricated evidence about a Texas facility — never addressed publicly. It will resurface in any S-1 and any acquirer's legal review, against the US-manufacturing story it now depends on.
Ring Pro sales rest on a conditional CBP determination (CT scans and records can be demanded at any time) and an unproven domestic-manufacturing capability — itself the subject of the falsified-evidence finding.
$70M vs. Oura's $11B and Whoop's $10.1B. Simultaneously promising an on-device-compute moonshot and admitting it can't afford to be profitable — on ~30x less capital than the leader.
Independent reviews (Reddit, Tom's Guide, GSMArena) report optimistic sleep scoring, “very off” activity tracking, and connectivity/durability complaints — corrosive for a “clinical/biomarker” brand and Labcorp's diagnostic thesis.
On-device AI, game-controller, and a developer platform “by end of September” collide with a ring's power, thermal, and antenna budget. High risk of vaporware that undercuts the entire raise narrative.
An India-HQ'd firm routing sleep, HRV, temperature, ovulation, and blood-biomarker data through AWS/Snowflake/MongoDB/CleverTap/Mixpanel, storable “in any country.” Reproductive-cycle data is among the most sensitive categories post-Dobbs. The “you own your data, no subscription” pitch is about access, not protection.
Ultrahuman is a real, profitable hardware business wrapped in a moonshot it cannot afford and a legal fight it has not escaped. The “no subscription” edge is genuine; the “ring as a computer” pitch is a chip vendor's fantasy priced at “end of September.” The two questions any buyer should lead with are the falsified-evidence finding now sitting over its US-manufacturing survival plan, and the $140M-ARR figure that does not reconcile with the last audited top line.
Based entirely on publicly available information, including the TechCrunch announcement of September 3, 2026. Every figure is tagged CONFIRMED, DERIVED, or EST in the underlying research; company-claimed metrics are not presented as verified.
